Ulcerative colitis (UC) is an illness that makes the inside of the large intestine and rectum swollen and can cause bleeding. This study is to see how well two medicines, risankizumab and vedolizumab, work for adults with moderate to severe UC. You can join if you haven't tried special treatments called targeted therapies (TaTs) before. About 530 adults will join worldwide, and you will be randomly given either risankizumab or vedolizumab. Risankizumab starts as an IV (into your vein) treatment, then switches to a shot under the skin. Vedolizumab is given as an IV for the entire study.
- Study Duration: About 69 weeks for risankizumab and 71 weeks for vedolizumab.
- Visits: Regular check-ups are needed to monitor safety and effectiveness.
- Eligibility: Must have active UC and not have received similar drugs before.
Participants might face more treatment tasks than usual care. Side effects and health changes will be watched closely. Make sure to discuss any concerns with your doctor before joining.